Skip to content

Clinical efficacy and safety analysis of S-1 or capecitabine concurrent radiotherapy in elderly patients with esophageal cancer

Clinical efficacy and safety analysis of S-1 or capecitabine concurrent radiotherapy in elderly patients with esophageal cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200060805
Enrollment
Unknown
Registered
2022-06-12
Start date
2022-06-01
Completion date
Unknown
Last updated
2023-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophageal cancer

Interventions

Sponsors

The Second Hospital of Hebei Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 89 Years

Inclusion criteria

Inclusion criteria: 1.Pathologically confirmed elderly patients with esophageal cancer >= 65 years old, including squamous carcinoma and adenocarcinoma; 2.Newly treated patients who are inoperable or refuse surgery; 3.KPS > 70, body surface area > 1.5m2, can eat more than semi-liquid diet; 4.Stage IB-IVA patients with AJCC stage 8; 5.Expected survival > 1 year; 6.Routine hematuria and liver, kidney, cardiopulmonary function showed no contraindations of radiotherapy and chemotherapy (WBC >= 3.5 x 10^9/ L, NE >= 1.5 x 10^9/ L, PLT >= 100 x 10^9/ L, Hb >= 100g/ L, ALT/AST <= 2.0 times the upper limit of normal value; 7.No history of serious hypertension or cardiovascular and cerebrovascular accidents; 8.Synchronous chemotherapy regimen was ticio and capecitabine.

Exclusion criteria

Exclusion criteria: 1.Neoadjuvant chemotherapy or other systemic therapy, such as targeted therapy, immunotherapy; 2.complicated with other malignant tumors; 3.severe heart, lung, liver and kidney function injury; A history of severe allergies; 4.Interstitial pneumonia or other infections affect the efficacy of radiotherapy and chemotherapy; 5.Stage IVb patients with distant metastasis; 6.tracheoesophageal fistula, esophageal perforation or possible invasion of the aorta; 7.People who cannot eat or have bad fluid quality.

Design outcomes

Primary

MeasureTime frame
Objective response rate (ORR);Overall survival (OS);

Secondary

MeasureTime frame
Progression-free survival (PFS);

Countries

China

Contacts

Public ContactChangxiaojing

The Second Hospital of Hebei Medical University

xiaojinge-mail@163.com+86 15803219514

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026